Related Experiment Video

Updated: Aug 23, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

[Molecular-target drug]

Saburo Sone1, Seiji Yano, Yasuhiko Nishioka

  • 1Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosiences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 27, 2004
PubMed

Insights

Biomarkers are crucial for evaluating new molecular-targeted cancer drugs, which often have cytostatic effects. This review discusses the significance and challenges of using biomarkers in clinical trials for targeted cancer therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Cancer metastasis involves complex processes like tumor growth, angiogenesis, invasion, and adhesion.
  • Molecular-targeted drugs aim to inhibit specific molecules driving cancer progression.
  • Clinical evaluation of these drugs faces challenges due to their cytostatic, rather than cytocidal, mechanisms.

Purpose:

  • To review the significance of biomarkers in the clinical evaluation of molecular-targeted cancer drugs.
  • To discuss the challenges associated with using biomarkers for efficacy assessment in early-phase clinical trials.
  • To explore how genomics and proteomics can expand the repertoire of targeted therapeutics.

Summary:

  • Molecular-targeted cancer drugs offer new therapeutic avenues but pose challenges in efficacy evaluation.
  • Biomarkers are essential for assessing the clinical benefit of cytostatic targeted agents.
  • Genomics and proteomics are advancing the development and evaluation of novel targeted therapies.

Impact:

  • Improved clinical trial design for molecular-targeted drugs.
  • Enhanced ability to predict patient response to targeted therapies.
  • Facilitation of personalized medicine approaches in oncology.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...